* Clearside Biomedical Inc CLSD.OQ reported a quarterly
adjusted
loss of 10 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -15 cents. The mean expectation of six analysts
for the quarter was for a loss of 13 cents per share. Wall
Street expected results to range from -16 cents to -12 cents per
share.
* Revenue fell 91.2% to $90.00 thousand from a year ago;
analysts
expected $126.67 thousand.
* Clearside Biomedical Inc's reported EPS for the quarter
was a
loss of 10 cents.
* The company reported a quarterly loss of $7.59 million.
* Clearside Biomedical Inc shares had fallen by 16.2% this
quarter and lost 6.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 0.7%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Clearside
Biomedical Inc is $5.00
This summary was machine generated from LSEG data August 13 at
01:33 a.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jan. 1 0001 -0.13 -0.10 Beat
Mar. 31 2024 -0.14 -0.15 Missed
Dec. 31 2023 -0.09 -0.08 Beat
Sep. 30 2023 -0.15 -0.15 Met